ARWR
Arrowhead Pharmaceuticals Inc
NASDAQ: ARWR · HEALTHCARE · BIOTECHNOLOGY
$70.53
+0.57% today
Updated 2026-04-29
Market cap
$9.88B
P/E ratio
44.08
P/S ratio
9.05x
EPS (TTM)
$1.60
Dividend yield
—
52W range
$12 – $77
Volume
2.2M
WallStSmart proprietary scores
56
out of 100
Grade: C+
Hold
Investment rating
8.7
Growth
A5.8
Quality
C+8.5
Profitability
A4.7
Valuation
C5/9
Piotroski F-Score
Moderate
0.3
Altman Z-Score
Distress
—
Industry rank
—
View all highly rated stocks (75+) →200 stocks currently score above 75
Price targets
Analyst target
$84.18
+19.35%
12-Month target
$48.05
-31.87%
Intrinsic (DCF)
—
Margin of safety
—
2 Strong Buy7 Buy3 Hold0 Sell0 Strong Sell
Price chart
X-Ray snapshot
Strengths
+ ROE 75.50% — strong efficiency
+ Free cash flow $11.33M — positive
+ Revenue growth 10,461.00% QoQ
Risks
- Altman Z 0.27 — distress zone
- P/E 44.08x — expensive valuation
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Revenue | $243.23M | $240.74M | $3.55M | $829.45M | $1.09B |
| Net income | $-176.49M | $-205.28M | $-599.49M | $-1.63M | $30.81M |
| EPS | — | — | — | — | $1.60 |
| Free cash flow | $-188.91M | $-330.63M | $-604.32M | $156.89M | $11.33M |
| Profit margin | -72.56% | -85.27% | -16,882.37% | -0.20% | 18.50% |
Recent insider activity
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| 2026-03-05 | HAMILTON, JAMES C | Sale | 10,000 | $64.19 |
| 2026-01-06 | O'BRIEN, PATRICK | Buy | 75,000 | — |
| 2026-01-06 | O'BRIEN, PATRICK | Sale | 540 | — |
Peer comparison
Smart narrative
Arrowhead Pharmaceuticals Inc trades at $70.53. representing a P/E of 44.08x trailing earnings. Our Smart Value Score of 56/100 indicates the stock is fair. The company scores 5/9 on the Piotroski F-Score. With an Altman Z-Score of 0.27, it sits in the distress. TTM revenue stands at $1.09B. with profit margins at 18.50%.
Frequently asked questions
What is Arrowhead Pharmaceuticals Inc's stock price?
Arrowhead Pharmaceuticals Inc (ARWR) trades at $70.53.
Is Arrowhead Pharmaceuticals Inc overvalued?
Smart Value Score 56/100 (Grade C+, Hold).
What is the price target of Arrowhead Pharmaceuticals Inc (ARWR)?
The analyst target price is $84.18, representing +19.4% upside from the current price of $70.53.
What is Arrowhead Pharmaceuticals Inc's revenue?
TTM revenue is $1.09B.
Piotroski F-Score?
5/9 — moderate financial health.
Altman Z-Score?
0.27 — distress.
Company info
SectorHEALTHCARE
IndustryBIOTECHNOLOGY
CountryUSA
ExchangeNASDAQ
CurrencyUSD
Quick metrics
P/S ratio9.05x
ROE75.50%
Beta1.27
50D MA$63.21
200D MA$47.76
Shares out0.14B
Float0.12B
Short ratio—
Avg volume2.2M
Performance
1 week—
1 month—
3 months—
YTD—
1 year—
3 years—
5 years—